Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Incyte Corporation (INCY) vs Williams Companies Inc (WMB) Price & Performance

Incyte CorporationTrade
Williams Companies IncTrade

Price performance (Past 24H)

Key statistics

Incyte Corporation vs Williams Companies Inc — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Williams Companies Inc trades at $73.75 (market cap $88.45B). The key difference: Williams Companies Inc is far larger — about 3.6× Incyte Corporation's market cap, and Williams Companies Inc pays a 2.9% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.

INCYWMB
Market Cap
$24.54B$88.45B
Sector
HealthEnergy
52-Week High
$129.93$79.40
52-Week Low
$81.61$56.51
Enterprise Value
$20.04B$119.07B
Dividend Yield
2.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Incyte Corporation

Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.

The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.

Williams Companies Inc

Williams Companies (WMB) trades at $73.60, up 2.44% with a bullish technical signal despite mixed earnings history. The company reported strong Q1 2026 results but missed Q2 estimates, while raising full-year EBITDA guidance to $8.4 billion. Analyst consensus remains strongly bullish with a $87.14 price target, supported by the recent $5.5 billion Momentum Midstream acquisition that enhances Gulf Coast exposure and supports 11% annual growth targets through 2030.

WMB presents a compelling investment case with strong profitability metrics (25.18% net margin, 24.02% ROE) and dividend stability ($2.10 annualized). Key risks include execution challenges from the Momentum integration, debt levels at 52.07% of assets, and potential volatility from energy market fluctuations. The stock offers 18% upside to consensus target with institutional support despite recent position reductions.

Returns comparison

Trailing returns across standard periods

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY

About Williams Companies Inc

Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.

Read more on WMB